<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="852">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629547</url>
  </required_header>
  <id_info>
    <org_study_id>2020008007</org_study_id>
    <nct_id>NCT04629547</nct_id>
  </id_info>
  <brief_title>Sleep Trial to Prevent Alzheimer's Disease</brief_title>
  <acronym>SToP-AD</acronym>
  <official_title>Sleep Trial to Prevent Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if treatment with the sleep aid suvorexant can&#xD;
      decrease the rate of amyloid-β (Aβ) accumulation in the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate if long-term treatment with suvorexant will slow amyloid-β&#xD;
      accumulation in the brain. Amyloid-β is a protein involved in the disease process leading to&#xD;
      Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of&#xD;
      amyloid-beta detected on brain scans (primary outcome).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2022</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Amyloid-β accumulation detected by brain scans compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>PET</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tau accumulation detected by brain scans compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>PET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma Amyloid-β compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>Blood collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Amyloid-β compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>Cerebrospinal fluid collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma tau compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>Blood collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF tau compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>Cerebrospinal fluid collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma p-tau compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>Blood collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF p-tau compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>Cerebrospinal fluid collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive performance compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by a cognitive composite consisting of the Digit Symbol Substitution Test, Animal Naming, Trails B and the Free and Cued Selective Reminding Test. Each test will be z-scored and then averaged together to make the composite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transcriptomics compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>blood and optional CSF collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolomics compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>blood and optional CSF collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proteomics compared to placebo</measure>
    <time_frame>24 months</time_frame>
    <description>blood and optional CSF collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiome compared to placebo</measure>
    <time_frame>214 months</time_frame>
    <description>optional stool sample collection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sleep</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Poor sleep treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 participants will be randomized to take suvorexant 20mg daily at h.s. for two years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor sleep control grop</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 participants will be randomized to take placebo daily at h.s. for two years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant 20 mg</intervention_name>
    <description>Suvorexant 20mg will be taken nightly for 24 months.</description>
    <arm_group_label>Poor sleep treatment group</arm_group_label>
    <other_name>Belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be taken nightly for 24 months.</description>
    <arm_group_label>Poor sleep control grop</arm_group_label>
    <other_name>inactive pill</other_name>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  Any race or ethnicity.&#xD;
&#xD;
          -  Participants must be age ≥65 years and able to sign informed consent.&#xD;
&#xD;
          -  Positive plasma amyloid beta test&#xD;
&#xD;
          -  PET PIB standard uptake value ratio (SUVR) between ≥1.42 to ≤3.&#xD;
&#xD;
          -  Clinical Dementia Rating (CDR) 0.&#xD;
&#xD;
          -  Willing and able to undergo study procedures.&#xD;
&#xD;
          -  Capacity to give informed consent and follow study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any sleep disorders other than insomnia, such as history or reported symptoms&#xD;
             suggestive of restless legs syndrome, narcolepsy, or parasomnia.&#xD;
&#xD;
          -  Actigraphic sleep efficiency ≥85%.&#xD;
&#xD;
          -  Abnormal movement of the non-dominant arm (would affect actigraphy data in&#xD;
             unpredictable ways).&#xD;
&#xD;
          -  STOP-Bang score ≥ 5.&#xD;
&#xD;
          -  Sleep disordered breathing if treated with PAP or AHI &gt;15.&#xD;
&#xD;
          -  Stroke.&#xD;
&#xD;
          -  History of hepatic or renal impairment.&#xD;
&#xD;
          -  HIV/AIDS.&#xD;
&#xD;
          -  Body mass index &gt;35.&#xD;
&#xD;
          -  History of substance abuse or alcoholism in the proceeding 6 months.&#xD;
&#xD;
          -  History of regular alcohol consumption 3 or more days a week over the last 6 months.&#xD;
             Regular alcohol consumption is defined as having more than 2 alcoholic beverages&#xD;
             within 3 hours of bedtime&#xD;
&#xD;
          -  History of presence of any clinically significant medical condition, behavioral or&#xD;
             psychiatric disorder, or surgical history based on medical record or participant&#xD;
             report that could affect the safety of the participant or interfere with study&#xD;
             assessments or in the judgement of the Principal-Investigator (PI) if participant is&#xD;
             not a good candidate.&#xD;
&#xD;
          -  Has any medical condition that, in the PI's opinion, could increase risk to the&#xD;
             participant, limit the participant's ability to tolerate the research procedures, or&#xD;
             interfere with the collection/analysis of the data (e.g. participants with severe&#xD;
             chronic back pain might not be able to lie still during the scanning procedures).&#xD;
             Potential medical conditions that will be exclusionary at the PI's discretion:&#xD;
&#xD;
               -  Cardiovascular disease requiring medication except for controlled hypertension.&#xD;
&#xD;
               -  Pulmonary disease.&#xD;
&#xD;
               -  Type I diabetes.&#xD;
&#xD;
               -  Neurologic or psychiatric disorder requiring medication.&#xD;
&#xD;
               -  Tobacco use.&#xD;
&#xD;
               -  Use of sedating medications.&#xD;
&#xD;
               -  Use of medications that interact with suvorexant (if cannot be discontinued)&#xD;
&#xD;
               -  Abnormal safety labs&#xD;
&#xD;
          -  History of current suicidal ideations.&#xD;
&#xD;
          -  Contraindications to PET, CT, or MRI (e.g. electronic medical devices, inability to&#xD;
             lie still for extended periods) that make it unsafe for the individual to participate.&#xD;
&#xD;
          -  All participants will be screened and excluded for neurologic or psychiatric&#xD;
             co-morbidities that could affect cognition as well as medical co-morbidities that may&#xD;
             prevent participants from undergoing PET/MRI, or cause excessive motion during&#xD;
             scanning.&#xD;
&#xD;
          -  Has hypersensitivity to AV-1451 and PIB or any of its excipients.&#xD;
&#xD;
          -  Severe claustrophobia.&#xD;
&#xD;
          -  Currently pregnant or breast-feeding. Women must agree to avoid becoming pregnant and&#xD;
             must agree to refrain from sexual activity or to use reliable contraceptive methods&#xD;
             for 24 hours following administration of Flortaucipir injection.&#xD;
&#xD;
          -  In the opinion of the PI, the participant should be excluded due to an abnormal&#xD;
             physical examination.&#xD;
&#xD;
          -  Must not have participated in any clinical trial involving a study drug or device&#xD;
             within the 30-days prior to study enrollment.&#xD;
&#xD;
          -  Must not participate in another drug or device study prior to the end of this study&#xD;
             participation.&#xD;
&#xD;
          -  Current or recent (within 12 months prior to screening) participation in research&#xD;
             studies involving radioactive agents such that the total research-related radiation&#xD;
             dose to the participant in any given year would exceed the limits set forth in the&#xD;
             U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1.&#xD;
&#xD;
        Exclusion criteria for optional lumbar punctures&#xD;
&#xD;
        -• Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to&#xD;
        lidocaine or disinfectant; prior central nervous system or lower back surgery).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Lucey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Univeristy School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Toedebusch, BS</last_name>
    <phone>3147470646</phone>
    <email>toedebuschc@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Toedebusch, BS</last_name>
      <phone>314-747-0646</phone>
      <email>toedebuschc@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brendan Lucey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>August 15, 2022</last_update_submitted>
  <last_update_submitted_qc>August 15, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Brendan Lucey</investigator_full_name>
    <investigator_title>Principal Investigator, Sleep Medicine Section Head</investigator_title>
  </responsible_party>
  <keyword>poor sleep</keyword>
  <keyword>Amyloid-Beta</keyword>
  <keyword>Insomnia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

